Opinion & analysis

The Case For CAR-T Grows As Responses Hold Up Longer Term

Scrip speaks with Pascal Touchon, Senior Vice President and Global Head, Cell & Gene Therapy at Novartis AG about the company’s encouraging successes with CAR-T therapies, as evidenced by 18-month data released during the December 2018 meeting of the American Society of Hematology.

The Case For CAR-T Grows As Responses Hold Up Longer Term

The Case For Agile Innovation In Health Care

The Blockbusters No One Talks About

The Advantages Of Providing Access To Unlicensed Medicines

Testing Ranitidine with Too Much Heat Could Generate NDMA, FDA Say

Telehealth, Wearables and Apps – Report 3

Telehealth, Wearables and Apps – Report 2

Telehealth, Wearables and Apps – Report 1

Telehealth Reforms Praised At Senate Hearing

Technology Gap Separates OTC Drug Firms From SelfCare Sales Growth

Takeda/Shire Merger: Five Things To Worry About

Takeda To Press On With Core R&D Strategy Post-Shire

Swiss Regulatory Change Takes Over 500 OTCs Out Of Pharmacy

Surprise As UK Notified Bodies Lose Major Part Of Their UK Role In Devices From March 29

Sunshine rules in the EU: Implications of a piecemeal approach

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

Strategy At Novartis: Culture Change As The ‘How’ Behind The ‘What’

Sterilization Facility Shutdowns Could Spell Medical Device Shortage; FDA Urges Firms To Assess ‘Downstream Impacts’

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

Standards, Not Predicates, Emphasized In Finalized Alternative 510(k) Pathway

Special Report: The Intersection Between Tech and Pharma (Part 1. Google)

Six Questions For McKinsey Executives On Pharma’s Digital Experience

Six Key New Commission Documents Relating To EU Directives And New Regulations

Serious Skin Reactions Reported with Ibuprofen Use in Europe

Scott Gottlieb Calls It Quits After An Active Tenure At US FDA

Schleifer, Yancopoulos And The $36 Billion Friendship

Schakowsky’s Loaded Cosmetics Bill Described as ‘Floor, Not a Ceiling’ for States to Build On

Sanofi’s New CEO Paul Hudson Poised To Write The Next Chapter

Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Rodan + Fields Concealed Prostaglandin Risks From Lash Boost Users – Class Action

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

Regulatory headaches: Brexit’s not the only thing you need to worry about

Reckitt Shaking Up Brain Health Market With Neuriva Dietary Supplement And Mobile App Launch In US

Reckitt Reaps ROI Reward In Geo-Targeted Symptoms App Promoting Mucinex, Delsym

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

Real-World Evidence: US FDA’s Prucalopride Review Shows Datasets’ Utility And Limitations

Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer

Ranitidine Recalls Begin In Europe As Regulators Take Action